 |
The BioCentury ShowAuthor: BioCentury
Tune in to BioCenturys in-depth conversations with global leaders who are advancing the future of medicine.Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues.The BioCentury Show is THE only place where BioCenturys experts join top innovators and global influencers to show how science is being turned into medicine.Don't miss this event, every two weeks, now available as a video webcast or audio podcast. Language: en-us Genres: Business, Life Sciences, Science Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
Ep. 107 - Forbion’s Slootweg on Europe Biotech, NewCos From Asia and Green Investing
Episode 107
Friday, 17 April, 2026
The European biotech ecosystem has gone through a substantial maturation process over the past 20 years, as VC funds such as Forbion have experienced exponential growth to fund the region’s innovation. But Forbion co-founder and managing director Sander Slootweg says there’s still more that can be done to fund future European innovations and improve Europe’s competitiveness globally.“We’ve observed in Europe that although we see great science, and we’ve been able to build great companies, in terms of the absolute magnitude of the ecosystem, we’re still lagging behind the U.S., and also China is coming up quickly,” Slootweg said in conversation with BioCentury's Stephen Hansen.View full story: https://www.biocentury.com/article/659150#EuropeanBiotech #VentureCapital #BiotechFunding #Bioeconomy #GlobalInnovation00:00 - Introduction01:34 - Forbion’s growth05:35 - Deal flow in Europe10:20 - Green Investing14:24 - Sourcing Asia Deals22:20 - Unlocking the EU’s Capital27:54 - Speeding Up Trials30:13 - Building a Thriving EU Market34:38 - Central & Eastern Europe
